Adverse  ||| S:0 E:8 ||| JJ
events  ||| S:8 E:15 ||| NNS
associated  ||| S:15 E:26 ||| VBN
with  ||| S:26 E:31 ||| IN
the  ||| S:31 E:35 ||| DT
healthcare  ||| S:35 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
patients  ||| S:49 E:58 ||| NNS
with  ||| S:58 E:63 ||| IN
multimorbidity  ||| S:63 E:78 ||| NN
admitted  ||| S:78 E:87 ||| VBD
to  ||| S:87 E:90 ||| TO
medium-long  ||| S:90 E:102 ||| JJ
stay  ||| S:102 E:107 ||| NN
hospitals  ||| S:107 E:117 ||| NNS
Since  ||| S:117 E:123 ||| IN
medical  ||| S:123 E:131 ||| JJ
practice  ||| S:131 E:140 ||| NN
involves  ||| S:140 E:149 ||| VBZ
risks ||| S:149 E:154 ||| NNS
,  ||| S:154 E:156 ||| ,
the  ||| S:156 E:160 ||| DT
aim  ||| S:160 E:164 ||| NN
of  ||| S:164 E:167 ||| IN
the  ||| S:167 E:171 ||| DT
health  ||| S:171 E:178 ||| NN
system  ||| S:178 E:185 ||| NN
is  ||| S:185 E:188 ||| VBZ
to  ||| S:188 E:191 ||| TO
promote  ||| S:191 E:199 ||| VB
and  ||| S:199 E:203 ||| CC
preserve  ||| S:203 E:212 ||| VB
health  ||| S:212 E:219 ||| NN
and  ||| S:219 E:223 ||| CC
to  ||| S:223 E:226 ||| TO
avoid ||| S:226 E:231 ||| VB
,  ||| S:231 E:233 ||| ,
relieve  ||| S:233 E:241 ||| NN
and  ||| S:241 E:245 ||| CC
treat  ||| S:245 E:251 ||| VB
disease ||| S:251 E:258 ||| NN
,  ||| S:258 E:260 ||| ,
while  ||| S:260 E:266 ||| IN
ensuring  ||| S:266 E:275 ||| VBG
the  ||| S:275 E:279 ||| DT
quality  ||| S:279 E:287 ||| NN
of  ||| S:287 E:290 ||| IN
care ||| S:290 E:294 ||| NN
.  ||| S:294 E:296 ||| .
Patient  ||| S:296 E:304 ||| JJ
safety  ||| S:304 E:311 ||| NN
is  ||| S:311 E:314 ||| VBZ
an  ||| S:314 E:317 ||| DT
essential  ||| S:317 E:327 ||| JJ
component  ||| S:327 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
the  ||| S:340 E:344 ||| DT
quality  ||| S:344 E:352 ||| NN
of  ||| S:352 E:355 ||| IN
care ||| S:355 E:359 ||| NN
.  ||| S:359 E:361 ||| .
To  ||| S:361 E:364 ||| TO
determine  ||| S:364 E:374 ||| VB
the  ||| S:374 E:378 ||| DT
incidence  ||| S:378 E:388 ||| NN
and  ||| S:388 E:392 ||| CC
prevalence  ||| S:392 E:403 ||| NN
of  ||| S:403 E:406 ||| IN
adverse  ||| S:406 E:414 ||| JJ
events  ||| S:414 E:421 ||| NNS
in  ||| S:421 E:424 ||| IN
hospitalized  ||| S:424 E:437 ||| JJ
patients  ||| S:437 E:446 ||| NNS
with  ||| S:446 E:451 ||| IN
multimorbidity  ||| S:451 E:466 ||| NN
in  ||| S:466 E:469 ||| IN
a  ||| S:469 E:471 ||| DT
medium-long  ||| S:471 E:483 ||| JJ
stay  ||| S:483 E:488 ||| NN
hospital ||| S:488 E:496 ||| NN
,  ||| S:496 E:498 ||| ,
to  ||| S:498 E:501 ||| TO
analyze  ||| S:501 E:509 ||| VB
the  ||| S:509 E:513 ||| DT
patients  ||| S:513 E:522 ||| NNS
and  ||| S:522 E:526 ||| CC
healthcare  ||| S:526 E:537 ||| JJ
characteristics  ||| S:537 E:553 ||| NNS
associated  ||| S:553 E:564 ||| VBN
with  ||| S:564 E:569 ||| IN
adverse  ||| S:569 E:577 ||| JJ
events ||| S:577 E:583 ||| NNS
,  ||| S:583 E:585 ||| ,
to  ||| S:585 E:588 ||| TO
assess  ||| S:588 E:595 ||| VB
their  ||| S:595 E:601 ||| PRP$
impact ||| S:601 E:607 ||| NN
,  ||| S:607 E:609 ||| ,
and  ||| S:609 E:613 ||| CC
to  ||| S:613 E:616 ||| TO
identify  ||| S:616 E:625 ||| VB
the  ||| S:625 E:629 ||| DT
possibilities  ||| S:629 E:643 ||| NNS
for  ||| S:643 E:647 ||| IN
prevention ||| S:647 E:657 ||| NN
.  ||| S:657 E:659 ||| .
We  ||| S:659 E:662 ||| PRP
performed  ||| S:662 E:672 ||| VBD
a  ||| S:672 E:674 ||| DT
retrospective  ||| S:674 E:688 ||| JJ
cohort  ||| S:688 E:695 ||| JJ
study  ||| S:695 E:701 ||| NN
in  ||| S:701 E:704 ||| IN
a  ||| S:704 E:706 ||| DT
medium-long  ||| S:706 E:718 ||| JJ
stay  ||| S:718 E:723 ||| NN
hospital  ||| S:723 E:732 ||| NN
in  ||| S:732 E:735 ||| IN
2004 ||| S:735 E:739 ||| CD
,  ||| S:739 E:741 ||| ,
and  ||| S:741 E:745 ||| CC
a  ||| S:745 E:747 ||| DT
prevalence  ||| S:747 E:758 ||| JJ
study  ||| S:758 E:764 ||| NN
once  ||| S:764 E:769 ||| IN
a  ||| S:769 E:771 ||| DT
year  ||| S:771 E:776 ||| NN
from  ||| S:776 E:781 ||| IN
2005  ||| S:781 E:786 ||| CD
to  ||| S:786 E:789 ||| TO
2008 ||| S:789 E:793 ||| CD
.  ||| S:793 E:795 ||| .
The  ||| S:795 E:799 ||| DT
incidence  ||| S:799 E:809 ||| NN
of  ||| S:809 E:812 ||| IN
patients  ||| S:812 E:821 ||| NNS
with  ||| S:821 E:826 ||| IN
adverse  ||| S:826 E:834 ||| JJ
events  ||| S:834 E:841 ||| NNS
directly  ||| S:841 E:850 ||| RB
related  ||| S:850 E:858 ||| VBN
to  ||| S:858 E:861 ||| TO
hospital  ||| S:861 E:870 ||| NN
care  ||| S:870 E:875 ||| NN
was  ||| S:875 E:879 ||| VBD
3.3 ||| S:879 E:882 ||| CD
% ||| S:882 E:883 ||| NN
,  ||| S:883 E:885 ||| ,
and  ||| S:885 E:889 ||| CC
the  ||| S:889 E:893 ||| DT
prevalence  ||| S:893 E:904 ||| NN
of  ||| S:904 E:907 ||| IN
patients  ||| S:907 E:916 ||| NNS
with  ||| S:916 E:921 ||| IN
adverse  ||| S:921 E:929 ||| JJ
events  ||| S:929 E:936 ||| NNS
associated  ||| S:936 E:947 ||| VBN
with  ||| S:947 E:952 ||| IN
health  ||| S:952 E:959 ||| NN
care  ||| S:959 E:964 ||| NN
was  ||| S:964 E:968 ||| VBD
5.8 ||| S:968 E:971 ||| CD
% ||| S:971 E:972 ||| NN
.  ||| S:972 E:974 ||| .
In  ||| S:974 E:977 ||| IN
both  ||| S:977 E:982 ||| DT
studies ||| S:982 E:989 ||| NNS
,  ||| S:989 E:991 ||| ,
extrinsic  ||| S:991 E:1001 ||| JJ
risk  ||| S:1001 E:1006 ||| NN
factors  ||| S:1006 E:1014 ||| NNS
and  ||| S:1014 E:1018 ||| CC
length  ||| S:1018 E:1025 ||| NN
of  ||| S:1025 E:1028 ||| IN
stay  ||| S:1028 E:1033 ||| NN
were  ||| S:1033 E:1038 ||| VBD
related  ||| S:1038 E:1046 ||| VBN
to  ||| S:1046 E:1049 ||| TO
a  ||| S:1049 E:1051 ||| DT
greater  ||| S:1051 E:1059 ||| JJR
risk  ||| S:1059 E:1064 ||| NN
of  ||| S:1064 E:1067 ||| IN
adverse  ||| S:1067 E:1075 ||| JJ
events ||| S:1075 E:1081 ||| NNS
.  ||| S:1081 E:1083 ||| .
In  ||| S:1083 E:1086 ||| IN
the  ||| S:1086 E:1090 ||| DT
incidence  ||| S:1090 E:1100 ||| JJ
study ||| S:1100 E:1105 ||| NN
,  ||| S:1105 E:1107 ||| ,
most  ||| S:1107 E:1112 ||| JJS
of  ||| S:1112 E:1115 ||| IN
the  ||| S:1115 E:1119 ||| DT
adverse  ||| S:1119 E:1127 ||| JJ
events  ||| S:1127 E:1134 ||| NNS
( ||| S:1134 E:1135 ||| -LRB-
68.7 ||| S:1135 E:1139 ||| NNP
% ||| S:1139 E:1140 ||| NN
)  ||| S:1140 E:1142 ||| -RRB-
were  ||| S:1142 E:1147 ||| VBD
moderate ||| S:1147 E:1155 ||| JJ
,  ||| S:1155 E:1157 ||| ,
while  ||| S:1157 E:1163 ||| IN
in  ||| S:1163 E:1166 ||| IN
the  ||| S:1166 E:1170 ||| DT
cross-sectional  ||| S:1170 E:1186 ||| JJ
study ||| S:1186 E:1191 ||| NN
,  ||| S:1191 E:1193 ||| ,
most  ||| S:1193 E:1198 ||| RBS
( ||| S:1198 E:1199 ||| -LRB-
84 ||| S:1199 E:1201 ||| CD
% ||| S:1201 E:1202 ||| NN
)  ||| S:1202 E:1204 ||| -RRB-
were  ||| S:1204 E:1209 ||| VBD
mild ||| S:1209 E:1213 ||| JJ
.  ||| S:1213 E:1215 ||| .
Fifty  ||| S:1215 E:1221 ||| JJ
percent  ||| S:1221 E:1229 ||| NN
of  ||| S:1229 E:1232 ||| IN
the  ||| S:1232 E:1236 ||| DT
AE  ||| S:1236 E:1239 ||| NNP
increased  ||| S:1239 E:1249 ||| VBD
the  ||| S:1249 E:1253 ||| DT
length  ||| S:1253 E:1260 ||| NN
of  ||| S:1260 E:1263 ||| IN
hospital  ||| S:1263 E:1272 ||| NN
stay ||| S:1272 E:1276 ||| NN
,  ||| S:1276 E:1278 ||| ,
and  ||| S:1278 E:1282 ||| CC
14.5 ||| S:1282 E:1286 ||| CD
%  ||| S:1286 E:1288 ||| NN
led  ||| S:1288 E:1292 ||| VBD
to  ||| S:1292 E:1295 ||| TO
readmission  ||| S:1295 E:1307 ||| VB
to  ||| S:1307 E:1310 ||| TO
the  ||| S:1310 E:1314 ||| DT
incidence  ||| S:1314 E:1324 ||| JJ
study ||| S:1324 E:1329 ||| NN
.  ||| S:1329 E:1331 ||| .
Most  ||| S:1331 E:1336 ||| JJS
of  ||| S:1336 E:1339 ||| IN
the  ||| S:1339 E:1343 ||| DT
adverse  ||| S:1343 E:1351 ||| JJ
events  ||| S:1351 E:1358 ||| NNS
detected  ||| S:1358 E:1367 ||| VBD
in  ||| S:1367 E:1370 ||| IN
both  ||| S:1370 E:1375 ||| DT
studies  ||| S:1375 E:1383 ||| NNS
required  ||| S:1383 E:1392 ||| VBN
additional  ||| S:1392 E:1403 ||| JJ
treatments  ||| S:1403 E:1414 ||| NNS
and  ||| S:1414 E:1418 ||| CC
procedures  ||| S:1418 E:1429 ||| NNS
to  ||| S:1429 E:1432 ||| TO
be  ||| S:1432 E:1435 ||| VB
performed ||| S:1435 E:1444 ||| VBN
.  ||| S:1444 E:1446 ||| .
Between  ||| S:1446 E:1454 ||| IN
30 ||| S:1454 E:1456 ||| CD
%  ||| S:1456 E:1458 ||| NN
and  ||| S:1458 E:1462 ||| CC
49 ||| S:1462 E:1464 ||| CD
%  ||| S:1464 E:1466 ||| NN
of  ||| S:1466 E:1469 ||| IN
the  ||| S:1469 E:1473 ||| DT
adverse  ||| S:1473 E:1481 ||| JJ
events  ||| S:1481 E:1488 ||| NNS
were  ||| S:1488 E:1493 ||| VBD
considered  ||| S:1493 E:1504 ||| VBN
avoidable ||| S:1504 E:1513 ||| NN
.  ||| S:1513 E:1515 ||| .
The  ||| S:1515 E:1519 ||| DT
incidence  ||| S:1519 E:1529 ||| NN
and  ||| S:1529 E:1533 ||| CC
prevalence  ||| S:1533 E:1544 ||| NN
of  ||| S:1544 E:1547 ||| IN
patients  ||| S:1547 E:1556 ||| NNS
with  ||| S:1556 E:1561 ||| IN
adverse  ||| S:1561 E:1569 ||| JJ
events  ||| S:1569 E:1576 ||| NNS
in  ||| S:1576 E:1579 ||| IN
medium-long  ||| S:1579 E:1591 ||| JJ
stay  ||| S:1591 E:1596 ||| NN
hospitals  ||| S:1596 E:1606 ||| NNS
were  ||| S:1606 E:1611 ||| VBD
lower  ||| S:1611 E:1617 ||| JJR
than  ||| S:1617 E:1622 ||| IN
those  ||| S:1622 E:1628 ||| DT
found  ||| S:1628 E:1634 ||| VBN
in  ||| S:1634 E:1637 ||| IN
acute-stay  ||| S:1637 E:1648 ||| JJ
hospitals ||| S:1648 E:1657 ||| NNS
.  ||| S:1657 E:1659 ||| .
The  ||| S:1659 E:1663 ||| DT
most  ||| S:1663 E:1668 ||| RBS
frequent  ||| S:1668 E:1677 ||| JJ
adverse  ||| S:1677 E:1685 ||| JJ
events  ||| S:1685 E:1692 ||| NNS
were  ||| S:1692 E:1697 ||| VBD
related  ||| S:1697 E:1705 ||| VBN
to  ||| S:1705 E:1708 ||| TO
medication  ||| S:1708 E:1719 ||| VB
in  ||| S:1719 E:1722 ||| IN
the  ||| S:1722 E:1726 ||| DT
incidence  ||| S:1726 E:1736 ||| JJ
studies  ||| S:1736 E:1744 ||| NNS
and  ||| S:1744 E:1748 ||| CC
with  ||| S:1748 E:1753 ||| IN
healthcare  ||| S:1753 E:1764 ||| NN
in  ||| S:1764 E:1767 ||| IN
the  ||| S:1767 E:1771 ||| DT
prevalence  ||| S:1771 E:1782 ||| JJ
studies ||| S:1782 E:1789 ||| NNS
.  ||| S:1789 E:1791 ||| .
Cohort  ||| S:1791 E:1798 ||| JJ
studies  ||| S:1798 E:1806 ||| NNS
are  ||| S:1806 E:1810 ||| VBP
the  ||| S:1810 E:1814 ||| DT
most  ||| S:1814 E:1819 ||| RBS
suitable  ||| S:1819 E:1828 ||| JJ
type  ||| S:1828 E:1833 ||| NN
of  ||| S:1833 E:1836 ||| IN
study  ||| S:1836 E:1842 ||| NN
to  ||| S:1842 E:1845 ||| TO
assess  ||| S:1845 E:1852 ||| VB
the  ||| S:1852 E:1856 ||| DT
impact  ||| S:1856 E:1863 ||| NN
of  ||| S:1863 E:1866 ||| IN
adverse  ||| S:1866 E:1874 ||| JJ
events ||| S:1874 E:1880 ||| NNS
.  ||| S:1880 E:1882 ||| .
Sequential  ||| S:1882 E:1893 ||| JJ
cross-sectional  ||| S:1893 E:1909 ||| JJ
studies  ||| S:1909 E:1917 ||| NNS
seem  ||| S:1917 E:1922 ||| VBP
to  ||| S:1922 E:1925 ||| TO
be  ||| S:1925 E:1928 ||| VB
useful  ||| S:1928 E:1935 ||| JJ
for  ||| S:1935 E:1939 ||| IN
identifying  ||| S:1939 E:1951 ||| VBG
and  ||| S:1951 E:1955 ||| CC
performing  ||| S:1955 E:1966 ||| VBG
surveillance  ||| S:1966 E:1979 ||| NN
of  ||| S:1979 E:1982 ||| IN
adverse  ||| S:1982 E:1990 ||| JJ
events  ||| S:1990 E:1997 ||| NNS
and  ||| S:1997 E:2001 ||| CC
allow  ||| S:2001 E:2007 ||| VB
strategies  ||| S:2007 E:2018 ||| NNS
to  ||| S:2018 E:2021 ||| TO
reduce  ||| S:2021 E:2028 ||| VB
these  ||| S:2028 E:2034 ||| DT
events  ||| S:2034 E:2041 ||| NNS
to  ||| S:2041 E:2044 ||| TO
be  ||| S:2044 E:2047 ||| VB
prioritized  ||| S:2047 E:2059 ||| NNS
and  ||| S:2059 E:2063 ||| CC
the  ||| S:2063 E:2067 ||| DT
effectiveness  ||| S:2067 E:2081 ||| NN
of  ||| S:2081 E:2084 ||| IN
improvement  ||| S:2084 E:2096 ||| NN
programs  ||| S:2096 E:2105 ||| NNS
to  ||| S:2105 E:2108 ||| TO
be  ||| S:2108 E:2111 ||| VB
assessed ||| S:2111 E:2119 ||| VBN
.  ||| S:2119 E:2121 ||| .
Consequently ||| S:2121 E:2133 ||| RB
,  ||| S:2133 E:2135 ||| ,
we  ||| S:2135 E:2138 ||| PRP
recommend  ||| S:2138 E:2148 ||| VBP
the  ||| S:2148 E:2152 ||| DT
introduction  ||| S:2152 E:2165 ||| NN
of  ||| S:2165 E:2168 ||| IN
this  ||| S:2168 E:2173 ||| DT
type  ||| S:2173 E:2178 ||| NN
of  ||| S:2178 E:2181 ||| IN
design  ||| S:2181 E:2188 ||| NN
to  ||| S:2188 E:2191 ||| TO
study  ||| S:2191 E:2197 ||| VB
adverse  ||| S:2197 E:2205 ||| JJ
events  ||| S:2205 E:2212 ||| NNS
in  ||| S:2212 E:2215 ||| IN
hospitals  ||| S:2215 E:2225 ||| NNS
specializing  ||| S:2225 E:2238 ||| VBG
in  ||| S:2238 E:2241 ||| IN
the  ||| S:2241 E:2245 ||| DT
care  ||| S:2245 E:2250 ||| NN
of  ||| S:2250 E:2253 ||| IN
patients  ||| S:2253 E:2262 ||| NNS
with  ||| S:2262 E:2267 ||| IN
chronic  ||| S:2267 E:2275 ||| JJ
diseases ||| S:2275 E:2283 ||| NNS
.  ||| S:2283 E:2285 ||| .
